Lexicon Pharmaceuticals (LXRX) News Today $1.12 -0.03 (-2.61%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.18 +0.06 (+5.80%) As of 05:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Lexicon Pharmaceuticals Down Today?Toggle Visibility of Why Is Lexicon Pharmaceuticals Down Today?Lexicon Pharmaceuticals (NASDAQ:LXRX) shares have risen on the back of fresh analyst upgrades and a strong Q2 2025 earnings beat, alongside encouraging updates on its clinical pipeline. Positive Sentiment: Citigroup raised its price target on LXRX from $1.20 to $1.90 and maintained a Buy rating, implying roughly 70% upside. Article Title Positive Sentiment: Analysts at American Banking News set a $3.67 price target on LXRX, indicating further upside potential. Article Title Positive Sentiment: Q2 2025 results beat expectations with EPS of $0.01 vs. a ($0.08) estimate and revenue of $28.9 million vs. $4.9 million expected. Article Title Positive Sentiment: Management reported progress on key R&D programs: pilavapadin partnership talks, LX9851 IND-enabling studies on track, and SONATA Phase 3 enrollment for hypertrophic cardiomyopathy due in 2026. Article Title Neutral Sentiment: Full Q2 2025 earnings call transcript is now available, offering deeper insights into corporate strategy. Article Title Posted 9h agoAI Generated. May Contain Errors. LXRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Lexicon Pharmaceuticals Reports Strong Q2 2025 ResultsAugust 7 at 9:51 PM | msn.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2025 Earnings Call TranscriptAugust 7 at 9:51 PM | msn.comLexicon Pharmaceuticals (LXRX): Citigroup Raises Price Target, Maintains Buy Rating | LXRX ...August 7 at 7:49 PM | gurufocus.comAnalysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) PT at $3.67August 7 at 2:21 AM | americanbankingnews.comQ2 2025 Lexicon Pharmaceuticals Inc Earnings Call TranscriptAugust 6 at 12:15 AM | gurufocus.comLexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call TranscriptAugust 6 at 1:16 PM | seekingalpha.comLexicon Pharmaceuticals (LXRX) Reports Strong Q2 Financial TransformationAugust 6 at 1:08 PM | gurufocus.comLexicon Pharmaceuticals Inc (LXRX) Reports Q2 2025 Earnings: EPS of $0. ...August 6 at 10:02 AM | gurufocus.comLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 6 at 10:02 AM | gurufocus.comLexicon Pharmaceuticals (LXRX) Surpasses Q2 Earnings ExpectationsAugust 6 at 10:01 AM | gurufocus.comLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business ...August 6 at 7:51 AM | gurufocus.comLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 6 at 7:30 AM | globenewswire.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of "Hold" by BrokeragesAugust 4, 2025 | marketbeat.comLexicon Pharmaceuticals (LXRX) Projected to Post Earnings on WednesdayJuly 31, 2025 | marketbeat.comLexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 31, 2025 | globenewswire.comMonaco Asset Management SAM Takes $338,000 Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)July 31, 2025 | marketbeat.comLexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025July 23, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above 200 Day Moving Average - Here's WhyJuly 23, 2025 | marketbeat.comH.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)July 20, 2025 | insidermonkey.comH.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)July 20, 2025 | msn.comLexicon Pharmaceuticals (NASDAQ:LXRX) Trading 6.6% Higher - Should You Buy?July 18, 2025 | marketbeat.comLexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)July 18, 2025 | globenewswire.comLexicon Pharmaceuticals, Inc. (LXRX) - Yahoo FinanceJuly 12, 2025 | finance.yahoo.comLexicon Pharmaceuticals Granted Nasdaq Compliance ExtensionJuly 3, 2025 | tipranks.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?July 2, 2025 | marketbeat.comWhile institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownershipJune 30, 2025 | finance.yahoo.comLXRX - Lexicon Pharmaceuticals Inc Price vs Fair Value - MorningstarJune 26, 2025 | morningstar.comMLexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at HC WainwrightJune 24, 2025 | marketbeat.comH.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stockJune 24, 2025 | investing.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving Average - Here's What HappenedJune 24, 2025 | marketbeat.comData Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)June 23, 2025 | globenewswire.comLexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)June 18, 2025 | globenewswire.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by AnalystsJune 15, 2025 | marketbeat.comLexicon Pharmaceuticals surges 67% following InvestingPro's Fair Value signalJune 8, 2025 | investing.comLexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWoodline Partners LP Lowers Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)May 29, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from AnalystsMay 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Acquires 7,758,371 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)May 22, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside PotentialMay 21, 2025 | insidermonkey.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Holdings Lifted by Tang Capital Management LLCMay 21, 2025 | marketbeat.comLexicon Pharmaceuticals’ Sotagliflozin: Promising Phase 3 Developments Justify Buy RatingMay 20, 2025 | tipranks.comSONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of CardiologyMay 19, 2025 | globenewswire.comLexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 19, 2025 | finanznachrichten.deLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 17, 2025 | finance.yahoo.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comLexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo NordiskMay 14, 2025 | msn.comLexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...May 14, 2025 | gurufocus.comQ1 2025 Lexicon Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2025 | gurufocus.comLexicon Pharmaceuticals (LXRX) Secures Major Licensing Deal with Novo NordiskMay 13, 2025 | gurufocus.comLexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.com Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.550.39▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼154▲LXRX Articles Average Week Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CLDX News DVAX News MNKD News INVA News NVAX News OPK News GERN News ZBIO News RIGL News MYGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
